Human chromosome ends are capped by shelterin, a protein complex that protects the natural ends from being recognized as sites of DNA damage and also regulates the telomere-replicating enzyme, telomerase 1-3 . Shelterin includes the heterodimeric POT1-TPP1 protein, which binds the telomeric single-stranded DNA tail 4-9 . TPP1 has been implicated both in recruiting telomerase to telomeres and in stimulating telomerase processivity (the addition of multiple DNA repeats after a single primer-binding event) [9] [10] [11] [12] [13] [14] . Determining the mechanisms of these activities has been difficult, especially because genetic perturbations also tend to affect the essential chromosome end-protection function of TPP1 (refs 15-17).
Human chromosome ends are capped by shelterin, a protein complex that protects the natural ends from being recognized as sites of DNA damage and also regulates the telomere-replicating enzyme, telomerase [1] [2] [3] . Shelterin includes the heterodimeric POT1-TPP1 protein, which binds the telomeric single-stranded DNA tail [4] [5] [6] [7] [8] [9] . TPP1 has been implicated both in recruiting telomerase to telomeres and in stimulating telomerase processivity (the addition of multiple DNA repeats after a single primer-binding event) [9] [10] [11] [12] [13] [14] .
Determining the mechanisms of these activities has been difficult, especially because genetic perturbations also tend to affect the essential chromosome end-protection function of TPP1 (refs 15-17) .
Here we identify separation-of-function mutants of human TPP1 that retain full telomere-capping function in vitro and in vivo, yet are defective in binding human telomerase. The seven separationof-function mutations map to a patch of amino acids on the surface of TPP1, the TEL patch, that both recruits telomerase to telomeres and promotes high-processivity DNA synthesis, indicating that these two activities are manifestations of the same molecular interaction. Given that the interaction between telomerase and TPP1 is required for telomerase function in vivo, the TEL patch of TPP1 provides a new target for anticancer drug development.
Genetic analysis of TPP1 regulation of telomerase is complicated by the potential of TPP1 mutations to uncap telomeres, which can give unnatural telomerase hyperextension or induce a DNA-damage response. Our search for separation-of-function mutants of TPP1 that would affect only its telomerase interactions was conducted on the TPP1 OB domain (TPP1(OB)), which is separate from its POT1 single-stranded DNA (ssDNA)-interaction domain ( Fig. 1a ) and previously implicated in telomerase interaction 13, 14 . We engineered 12 single amino-acid mutants and two double mutants of TPP1(OB), choosing residues that are both conserved among mammalian TPP1 proteins and reside on the protein surface 9 ( Supplementary Fig. 1a, b) . All mutant and wild-type proteins were expressed recombinantly in Escherichia coli and purified ( Supplementary Fig.1c ; see Methods).
The POT1-TPP1 heterodimer has a higher affinity for telomeric ssDNA than does POT1 alone 9 , which is consistent with the role of this complex in protecting single-stranded telomeric DNA from the DNAdamage response machinery 15 . Quantitative DNA-binding experiments demonstrated that all the mutant proteins, like wild-type TPP1, were able to enhance POT1-DNA affinity ( Fig. 1b and Supplementary Fig.  2a ). Furthermore, all TPP1 mutants formed stable POT1-TPP1-ssDNA ternary complexes in electrophoretic mobility shift assays (Supplementary Fig. 2b) . These results suggest that the TPP1(OB) surface mutations do not disrupt the overall structure or the DNA-end protection function of TPP1.
Addition of purified POT1-TPP1 to telomerase enzyme activity assays enhances telomerase processivity 2-3-fold in vitro 9 . We developed a new direct telomerase assay in which TERT, TR, TPP1 and POT1 were recombinantly co-expressed in human cells. Lysates from these cells were used in direct telomerase activity assays involving extension of primer a5 (TTAGGGTTAGCGTTAGGG; the underlined G-to-C mutation ensured positioning of the POT1-TPP1 complex at the 59 portion of the DNA primer, thereby providing a homogenous substrate for telomerase extension 9 ). The 14 TPP1 mutants varied substantially in their stimulation of processivity; some such as S106A, S111A and R175V, resulted in long extension products indicative of high processivity, similar to wild-type TPP1, but others, such as E169A/ E171A and L212A, resulted in low-processivity patterns similar to that with no TPP1 added ( Fig. 1c ). Quantification of data ( Fig. 1d ) showed that several TPP1 mutants gave significantly decreased processivity (P , 0.005). Western blot analysis showed that TERT, POT1 and TPP1 proteins were expressed at similar levels across all transfections ( Fig. 1e ). Note that processivity, unlike activity, is not influenced by enzyme concentration.
As an independent test of processivity, lysates from HEK 293T cells transiently overexpressing telomerase were supplemented with purified POT1 and TPP1 proteins before the telomerase assay, as described previously 9, 11, 18 (Supplementary Fig. 3 ; see also alternative quantification of processivity in Supplementary Fig. 4 ). This traditional assay gave results in agreement with the new co-transfection method. We also analysed the 14 TPP1 mutants using a primer with a purely telomeric sequence and a different sequence permutation (GGTTAGGGTTAG GGTTAG); we obtained essentially the same results as with primer a5 ( Supplementary Fig. 5 ), verifying that the TPP1 mutant phenotype was not primer specific. All three assays identified the same separation-offunction mutants of TPP1 (L104A, D166A/E168A, E169A/E171A, R180A, L183A and L212A), with E215A and R208V being intermediate and the other mutants having wild-type activity. Further dissection of the two double mutants into four single mutants revealed that E168, E169 and E171, but not D166, were important for telomerase stimulation ( Supplementary Fig. 3 ). Most of the TPP1 mutants that were defective in processivity also gave a statistically significant decrease in activity ( Supplementary Fig. 3b ). In agreement with previous results 9 , the stimulation of activity (and its dependence on specific TPP1 residues) was observed even in the absence of added POT1 protein ( Supplementary Fig. 6 ).
The effects of TPP1 mutations might be explained by disruption of a TPP1-telomerase interaction. To test this directly, we developed a co-immunoprecipitation assay involving co-transfection of Flag-TPP1 and untagged telomerase (TERT plus TR) in HeLa-EM2-11ht cells. Inspection and quantification by immunoblot of proteins coprecipitated with anti-Flag beads shows that TERT, but not actin, was associated with Flag-TPP1 ( Fig. 2a , compare lanes 1 and 2). More TERT protein was co-precipitated with Flag-TPP1 when POT1, the in vivo binding partner of TPP1, was also present (compare lanes 2 and 4). Addition of primer a5 (a ligand for POT1-TPP1 and a substrate for telomerase) to lysates containing Flag-POT1 and Flag-TPP1 before immunoprecipitation increased the TPP1-telomerase interaction by ,2.5-fold compared to the basal interaction in the absence of POT1 and a5 DNA (compare lanes 2 and 6). The enhanced interaction between telomerase and POT1-TPP1 is unlikely to be occurring indirectly via bridging of TPP1 and telomerase by POT1-DNA, because Flag-POT1 did not pull down telomerase even in the presence of a5 DNA (lane 5).
The interaction between TPP1 and telomerase was reduced when either TR or TERT was omitted from co-transfections ( Supplementary  Fig. 7a, b ). These results indicate that TPP1 interacts with telomerase optimally in the context of the fully assembled RNP. The TEN (telomerase essential N-terminal) domain of TERT has been implicated in a functional interaction with POT1-TPP1 19 and in binding to TPP1(OB) 20 . However, deletion of the TEN domain or mutating G100V (ref. 19) did not abolish telomerase binding ( Supplementary Fig. 7c and ref. 21) . These data indicate that the observed immunoprecipitation of telomerase with TPP1 involves contacts both within and outside the TEN domain of TERT, which is consistent with the implication of C-terminal TERT residues in TPP1(OB)-mediated recruitment of telomerase to telomeres 20 .
When the TPP1 mutants were tested for binding telomerase (Fig. 2b , c), there was strong correlation with the telomerase stimulation results. Five of the six mutants that showed a defect in telomerase stimulation in vitro also showed defects in telomerase association in the presence of POT1 and DNA primer, and the intermediate mutant E215A was also defective in binding. An exception was mutant L104A, which showed wild-type levels of associated telomerase.
When the separation-of-function mutations that fail to stimulate processivity and also interfere with telomerase binding are mapped on the surface of the TPP1(OB) structure, the seven critical amino acids (E168, E169, E171, R180, L183, L212 and E215) cluster to reveal a patch on the protein surface (orange in Fig. 2d ). We name this conserved surface the TEL patch (TPP1 glutamate (E) and leucine (L)-rich patch). The fact that the TEL patch promotes both processivity and indicates transfection without POT1 and TPP1. The number of telomeric repeats added to primer are indicated along the left. d, Processive extension (.15 repeats/total) with TPP1 mutants relative to that with wild-type TPP1 (green line) obtained from three independent sets of experiments (as in panel c); error bars indicate s.d. Stimulation of processivity is assessed relative to the 'no POT1-TPP1' negative control (red line). Two-tailed student's t-test with respect to R175V: *P , 0.02, **P , 0.005. Red labels indicate significantly defective; green labels indicate not significantly defective. e, Immunoblot of lysates used in panel c probed with anti-Flag antibody-HRP conjugate shows uniform expression.
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telomerase binding fulfils a prediction of a previous model for telomerase processivity 11 . The 'back face' of TPP1(OB) (bottom view of Fig. 2d ) contains amino acids not involved in binding telomerase.
Previously, knockdown of TPP1 in human HTC75 cells resulted in telomere lengthening 7 , whereas skin keratinocytes from Tpp1 D/D K5-cre newborn mice displayed telomere shortening 12 . However, loss of both end-protection and telomerase-regulatory functions of TPP1 complicates interpretation of such studies. To test how the TPP1-telomerase interaction influences telomere maintenance under conditions where chromosome end protection is unperturbed, we constructed stable cell lines containing a single-copy gene cassette with a bidirectional tetracycline-inducible promoter (Ptet-bi, Fig. 3a ). The promoter expresses both a short hairpin RNA (shRNA; shTPP1) to knockdown endogenous TPP1 (Fig. 3b, c and Supplementary Fig. 8a -c) and a shRNA-resistant version of Flag-TPP1 (Flag-TPP1* or wild type*; Fig. 3d and Supplementary Fig. 8a, d ). E169A/E171A*, R175V* and L212A* cell lines express shRNA-resistant versions of the various mutant TPP1 proteins (asterisks indicate shRNA-resistant mRNAs). We also constructed a similar set of cell lines in which various TPP1 proteins were ectopically expressed without knocking down the endogenous TPP1 (Supplementary Figs 9a, b and 10a, b). Overexpression of TPP1 as described above (,25-fold; data not shown) could potentially sequester shelterin components from telomeres, leading to the appearance of telomere-dysfunction-induced foci (TIFs) 13 . However, expression of the TPP1 mutants resulted in the same low levels of TIFs as wild type ( Supplementary Fig. 11 ). These data are consistent with the unaltered POT1-DNA binding properties of the TPP1(OB) mutants ( Fig. 1b ) and with a previous study showing that deletion of the entire TPP1(OB) domain fails to elicit chromosome end-deprotection 14 .
The stable cell lines expressing wild-type and control (R175V) Flag-TPP1 showed a robust increase in telomere length over 81 population doublings (,40 bp per population doubling) in a doxycycline-dependent (Flag-TPP1 expression-dependent) manner, whereas the telomeres of the untransfected cell line were stable (Fig. 3e , f and Supplementary Figs 9c, d and 10c, d). In contrast, the telomeres of cell lines expressing E169A/E171A and L212A did not change in length over 81 population doublings. This result is in full agreement with our data showing that E169A/E171A and L212A have a greatly diminished ability to stimulate telomerase ( Fig. 1 ) and to associate with telomerase ( Fig. 2 ), but that R175V behaves like the wild-type protein. We conclude that TPP1 increases telomerase action in vivo and that the TEL patch of TPP1 is necessary for this effect.
We tested whether the inability of the E169A/E171A and L212A mutants to stimulate telomere lengthening was due to their inability to recruit telomerase to telomeres. The cell lines stably co-expressing shTPP1 and TPP1* (wild type*, E169A/E171A*, R175V*, or L212A*) were transfected with expression plasmids encoding TERT and TR and analysed by co-immunofluorescence (co-IF) and immunofluorescencefluorescence in situ hybridization (IF-FISH). As expected, wild-type and all mutant Flag-TPP1 proteins localized to telomeres (Supplementary Fig. 12 ). Telomerase was efficiently recruited to telomeres containing wild-type and R175V proteins, as indicated by the colocalization of TR and Flag-TPP1 ( Fig. 4a, b ). By the same criterion, the E169A/E171A* and L212A* cell lines showed reduced levels of telomerase recruitment to telomeres. Instead, the TR foci in E169A/ E171A* and L212A* cells resided in Cajal bodies (marked by coilin; Fig. 4c ), indicating that the corresponding TPP1 mutations prevent telomerase in Cajal bodies from being delivered to telomeres. TEL patch mutations also reduced recruitment of endogenous TR to telomeres ( Supplementary Fig. 13 ).
We conclude that a small patch of amino acids on the surface of the chromosome-end-binding protein TPP1, the TEL patch, binds telomerase to enable both its recruitment to telomeres and its highprocessivity extension of telomeric DNA. While this manuscript was under review, two groups independently reported the involvement of portions of the TEL patch in telomerase association 21 and telomerase recruitment 20 . 
In the simplest model, the TEL patch binds telomerase directly. If there were a bridging molecule, it would probably be an abundant cellular component, because TPP1-telomerase binding is robust under conditions of TPP1 and telomerase overexpression, where any telomerase-specific factors would be substoichiometric. There is precedence for such a bridging molecule in Schizosaccharomyces pombe, where Ccq1 physically connects Tpz1 (the S. pombe TPP1) to telomerase [22] [23] [24] . However, there is no identifiable homologue of Ccq1 in humans (see Supplementary Discussion for comparison with telomerase recruitment in budding yeast).
The substantial reduction of telomerase recruitment by subtle mutations in the TEL patch of TPP1 indicates the potential for novel strategies to inhibit telomerase for cancer therapy. By targeting the TEL patch, instead of telomerase itself, a compound could potentially inhibit telomerase action only at telomeres without interfering with other hTERT functions 25, 26 . Furthermore, such an inhibitor should not perturb genomic stability in normal cells lacking telomerase, because the TEL patch is physically and functionally separate from the portion of TPP1 engaged in chromosome end-protection.
METHODS SUMMARY
All experiments involving recombinant TPP1 expressed in bacteria 9 used TPP1(N) (amino acids 87-334), which recapitulates all in vitro functions of the full-length human protein 9 . Experiments involving TPP1 expressed in human cells used full-length TPP1 that we define as starting from amino acid Met 87 (refs 9, 14) ( Fig. 1a ). Telomerase was obtained from HEK 293T cells transfected with human TERT and TR plasmids 18 
METHODS
All experiments involving recombinant TPP1 expressed in bacteria 9 used TPP1(N) (amino acids 87-334), which recapitulates all in vitro functions of the full-length human protein 9 . Experiments involving TPP1 expressed in human cells used fulllength TPP1 that we define as starting from amino acid Met 87 (refs 9, 14) ( Fig. 1a) .
Oligonucleotides. Synthetic oligonucleotides used in gel-shift, filter-binding and telomerase activity assays were purchased from Integrated DNA Technologies and resuspended in 10 mM Tris-Cl (pH 8.0) to obtain 50 mM stocks that were stored at 220 uC and diluted to required concentrations immediately before use. Plasmid constructs for cell-based assays. Mammalian cell expression plasmids encoding human TERT (pTERT-cDNA6/Myc-His C 18 ) and human TR (phTR-Bluescript II SK(1) 18 ) were a gift from J. Lingner. The pd1gfpPtetmiR and pTet-BI4 vectors, and HeLa-EM2-11ht cell line were obtained from Tet Systems Holdings GmbH & Co. KG upon signing a materials transfer agreement. The pTet-BI4 vector, which contains a bidirectional tetracycline-inducible promoter (Ptet-bi), allows for doxycycline (dox)-dependent expression (Tet-on) of genes in the HeLa-EM2-11ht cell line, which constitutively expresses the reverse tetracycline-controlled transactivator gene 28 . The pIRES2-EGFP Rac2 plasmid 29 that was used to PCR-amplify IRES-GFP was a gift from G. Johnson. shRNA and shRNA-resistant constructs of TPP1. The target sequence for shRNAs illustrated in Supplementary Fig. 8 are as follows: shRNA-A, 59-CGT TGCATCCGCTGGGTGT-39; shRNA-B, 59-TGGAGTTCAAGGAGTTTGT-39; shRNA-C, 59-GACTTAGATGTTCAGAAAA-39 13 . shTPP1, shown in Fig. 3 , contains two repeats each of shRNA-B and shRNA-C arranged in tandem. shRNAresistant mutations were introduced by site-directed mutagenesis using the following primers (and their reverse complements): shRNA-A resistant, 59-GGA AACCCGGGCCCccTtCAcCCGCTcGGaGTgGCCGTGGGGATG-39; shRNA-B resistant, 59-CCCCAGAAACCTAGCCTcGAaTTtAAGGAaTTcGTcGGGTTG CCCTGCAAG-39; shRNA-C resistant, 59-GGGTGCCTGGTTGCAACCAAG AtcTtGATGTcCAaAAgAAGCTCTATGACTGCCTTGAGG-39; where lower-case indicates silent mutations introduced in the TPP1 gene to make the mRNA resistant to the indicated shRNA. In addition to possessing the duplex RNA sequence for silencing, all shRNA constructs also contained critical sequence elements derived from microRNA mR-30 for increasing the efficiency of RNA silencing 30 .
Immunoblotting. Standard immunoblot protocols were used with the following antibodies at specified dilutions: mouse monoclonal anti-Flag M2-HRP conjugate (Sigma; A8592; 1:10,000), rabbit monoclonal TERT (C-term) antibody (Epitomics; 1531-1; 1:500), mouse monoclonal anti-b-actin antibody (Sigma; A5441; 1:10,000), and mouse monoclonal TPP1 antibody (Abnova; H00065057-M02; 1:1,000). Secondary horseradish peroxidase-conjugated goat antibodies against rabbit IgG (Santa Cruz Biotechnology; 1:10,000) or donkey antibodies against mouse IgG (Jackson Immunoresearch; 1:10,000) were used to reveal the primary antibodies using chemiluminescence detection by ECL plus reagents (GE Healthcare Lifesciences). The data were visualized and quantified using a FluorChem HD2 (Alpha Innotech) imaging system. Molecular cloning. C-terminally 33-Flag-tagged human TPP1 and C-terminally 33-Flag-tagged human POT1 genes were amplified from human TPP1 cDNA (Open Biosystems; Thermo Scientific) and POT1 cDNA (pET-Smt3-POT1; unpublished results), respectively, using forward primers containing a NotI site upstream of the start codon and reverse primers that contained: a stop codon-toserine mutation, a DNA sequence coding for a 33-Flag tag, and a terminal SalI site at the 59 end. For transient transfection experiments, the PCR fragments were restriction digested and cloned upstream of the IRES-GFP in the pTet-IRES-eGFP-BI4 vector (obtained by cloning a PCR-amplified and restriction digested IRES-eGFP fragment into pTet-BI4) to furnish p33-Flag-TPP1-BI4 and p33-Flag-POT1-BI4 plasmids. Using this construct, TPP1 and GFP proteins are synthesized as separate polypeptides in the cell. For stable transfection purposes, the TPP1-IRES-GFP fragment was subcloned from the p33-Flag-TPP1-BI4 vector to the pd1gfpPtetmiR vector (replacing the existing d1GFP gene in the vector) that contains the F/F3 Flp recombination sites flanking the multiple cloning site to yield p33-Flag-TPP1-F3 constructs that were subsequently used for stable transfection. p33-Flag-TERT-cDNA6/Myc-HisC, which contains an N-terminal 33-Flag tag immediately upstream from the TERT start codon, was obtained via sitedirected mutagenesis of pTERT-cDNA6/Myc-HisC 18 . For stable co-transfections with shTPP1 and shTPP1-resistant TPP1, the bi-directionality of the pTet promoters of pTet-IRES-eGFP-BI4 and pd1gfpPtetmiR was exploited. Whereas the TPP1 constructs were cloned as mentioned above, the shTPP1 was cloned between the SpeI/NheI sites of the second multiple cloning site downstream of the second pTet element. The shTPP1-resistant mutations were made by site-directed mutagenesis (as detailed below). Site-directed mutagenesis. Missense mutations were introduced into the TPP1 gene using fully complementary mutagenic primers (QuickChange site-directed mutagenesis kit from Agilent Technologies). For the generation of TPP1(N) mutants for overexpression in bacteria, the pET-Smt3-TPP1(N) plasmid 9 was used as the template in the PCR, whereas for expression in the HeLa-EM2-11ht cell line, p33-Flag-TPP1-BI4 was used as the template in the PCR. The TPP1 genes in the mutant plasmids were sequenced completely to verify the presence of the intended mutation(s) and exclude the acquisition of unwanted changes during PCR amplification and cloning. Protein purification. Purified mutant and wild-type Smt3-TPP1(N) fusion proteins were obtained from soluble lysates of isopropyl b-d-thiogalactopyranosideinduced BL21(DE3) cells after nickel-agarose chromatography, treatment with Ulp1 protease to cleave the Smt3 tag 31 and size-exclusion chromatography 9 . Purified recombinant human POT1 protein was obtained from baculovirusinfected insect cells as described previously 8 . Gel-shift and filter-binding assays. Electrophoretic mobility shift assays and filter-binding assays of POT1-TPP1-oligonucleotide complexes were performed exactly as described previously 32 . Cell culture. All human cells were cultured at 37 uC with 5% CO 2 . HEK 293T cells were cultured in growth medium containing Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM glutamax (Life Technologies), 100 units ml 21 penicillin, and 100 mg ml 21 streptomycin. HeLa-EM2-11ht and stable cell lines derived from it were propagated in growth medium containing DMEM, 10% FBS, 2 mM glutamax, 1 mM sodium pyruvate, 100 units ml 21 penicillin and 100 mg ml 21 streptomycin. Doxycycline was added to a final concentration of 200 ng ml 21 for induction of pTet-driven genes. Telomerase preparations. Telomerase preparations from HEK 293T cell extracts (super-telomerase) were obtained from transient transfection of TERT and TR using a published protocol 18 . For telomerase preparations from HeLa-EM2-11ht cells, 300,000 cells per well of a 6-well plate were seeded and transfected 42 h later using Lipofectamine 2000 (Invitrogen) and indicated plasmid DNA using the manufacturer's recommendation. 1 mg p33-Flag-TERT-cDNA6/Myc-HisC and 3 mg phTR-Bluescript II SK(1) 18 were added per transfection. For transfections involving POT1 or TPP1, 1 mg of p33-Flag-POT1-BI4 or p33-Flag-TPP1-BI4 was added per transfection. In control transfections where POT1 and TPP1 were omitted, pTet-BI4 28 (empty vector) was included. Medium was removed after 5 h and exchanged with fresh medium containing 200 ng ml 21 doxycycline to induce TPP1 and/or POT1 expression from the tetracycline-driven promoter. After 48 h of transfection, the cells were trypsinized, washed with phosphate buffered saline (PBS), re-suspended in 100 ml CHAPS lysis buffer 11 containing 1 ml of RNasin plus (Promega), mixed with rocking on a nutator at 4 uC for 20 min, and centrifuged (13,600 r.p.m., 10 min) to remove cell debris. Aliquots of the soluble cell lysates were flash frozen in liquid nitrogen and stored at 280 uC. Telomerase activity assays. Telomerase reactions were carried out as 20 ml reactions containing: 50 mM Tris-Cl (pH 8.0), 30 mM KCl, 1 mM MgCl 2 , 1 mM spermidine, 5 mM b-mercaptoethanol, the indicated concentration of primer a5 or b 9 , 500 mM dATP, 500 mM dTTP, 2.92 mM unlabelled dGTP, 0.33 mM radiolabelled dGTP (3,000 Ci mmol 21 ), and 3 ml of super-telomerase cell extract (or telomerase from HeLa-EM2-11ht cell extracts) at 30 uC for 30 min. Reactions were stopped with buffer containing 100 ml of 3.6 M ammonium acetate, 20 mg of glycogen and a 59 end-labelled (7.5 c.p.m. ml 21 ) 18mer oligonucleotide loading control, and precipitated with ethanol. The pellets were re-suspended in 10 ml H 2 O and 10 ml of loading buffer (95% formamide, 5% H 2 O, loading dye), heated at 95 uC for 10 min, and loaded onto a 10% acrylamide, 7 M urea, 13 TBE sequencing gel. Gels were run at 90 W for 1.75 h, dried, exposed to an image plate and imaged on a phosphorimager (TyphoonTrio). The data were analysed using Imagequant TL software and telomerase activities quantified as described previously 11 . Processivity calculations were performed as described previously 11 (Supplementary Fig. 4) although it was not possible to include the higher molecular weight products on the gel in these calculations due to severe band overlap. To include the contributions of these upper bands (which are the result of the highly processive action of telomerase; data not shown) in processivity measurements, we defined a '151' relative processivity term as the fraction of the total activity present in bands resulting from 15 (number chosen arbitrarily to define the lower limit of high processivity) or more telomeric repeats added by telomerase ( Fig. 1d and Supplementary Fig. 3c ), noting that the '151' method does not correct for the greater number of G nucleotides (three per repeat) in the upper bands compared to lower bands. Co-immunoprecipitation experiments. The protocol was adapted from a previously published protocol 7 . HeLa-EM2-11ht cells were seeded and transfected as stated above for telomerase preparations. After 24 h of transfection, cells were washed with PBS, dislodged with a cell-scraper using 400 ml ice-cold lysis buffer (50 mM Tris-Cl (pH 7.4), 20% glycerol, 1 mM EDTA, 150 mM NaCl, 0.5% Triton X-100, 0.02% SDS, 1 mM dithiothreitol, 2 mM phenylmethylsulphonyl fluoride, complete protease inhibitor cocktail (Roche)) and kept on ice. After 5 min, 20 ml of 5 M NaCl was added and mixed. After another 5 min on ice, 420 ml of ice-cold water was added and mixed before immediate centrifugation (13,600 r.p.m., 10 min). Supernatants were collected and used directly for immunoprecipitation. Lysate (40 ml) added to 40 ml of 43 LDS sample loading buffer (Invitrogen) was kept aside for analysis of 'input' samples. Anti-Flag/M2 affinity gel beads (50 ml; Sigma) pre-incubated with 100 mg ml 21 of bovine serum albumin in PBS were added to lysate prepared from each well of a 6-well plate. Mixtures were mixed with rocking on a nutator for 2 h at 4 uC. Beads were washed three times with 1:1 diluted lysis buffer and proteins were eluted with 180 ml 1:1 diluted 43 LDS sample loading buffer (Invitrogen) for analysis of 'beads' samples. All 'input' (10 ml) and 'beads' (15 ml) samples were heated at 90 uC for 12-14 min and analysed by SDS-PAGE and immunoblotting. Stable cell line generation using HeLa-EM2-11ht cells and p33-Flag-TPP1-F3 plasmids. Detailed protocols for stable transfection of HeLa-EM2-11ht cells are reported elsewhere 33 . HeLa-EM2-11ht cells were co-transfected in a 6-well format using either Lipofectamine 2000 (Life Technologies) or TransIT (Mirus) using the manufacturer's protocol with 1 mg each of the p33-Flag-TPP1-F3 (containing wild type, E169A/E171A, R175V, or L212A mutants for experiments in Supplementary Fig. 9 , and containing shTPP1 and shTPP1-resistant wild type, E169A/E171A, R175V, or L212A mutants for experiments in Fig. 3 ), and 1 mg of a plasmid expressing Flp recombinase and conferring puromycin resistance. Twelve hours post-transfection, transfected cells were selected for 36 h using 5 mg ml 21 puromycin. Subsequently, fresh medium lacking puromycin but including 50-100 mM ganciclovir (Sigma-Aldrich) was added and negative selection was conducted for 10 days. Next, 12 individual clones were picked from each transfection and expanded. To verify the identity of the clone and distinguish it from false-positive clones that survived selection, a small aliquot of cells was induced overnight with 200 ng ml 21 doxycycline and observed under a fluorescence microscope ( Supplementary Fig. 10a ). Positive clones were selected based on green fluorescence arising from their IRES-GFP locus downstream of the Flag-TPP1 gene (Fig. 3a) and also confirmed using flow cytometry ( Supplementary Fig.  10b ). The typical efficiency of cloning (positive clones/total survivors) using this protocol was between 8% and 50%. Positive clones were expanded until they grew to confluency in 10-cm culture dishes and induced with 200 ng ml 21 doxycycline for studying the effect of TPP1 mutations in cells. Telomere length analysis. Genomic DNA was isolated from confluent 10-cm culture dishes of the original HeLa-EM2-11ht cells and Flag-TPP1 expressing stable cell lines using the GenElute kit (Sigma). Genomic DNA (1.5 mg) was restriction digested with frequent cutters Hinf1 and Rsa1 overnight at 37 uC. The DNA digests were run on a 0.8% Agarose-13 TBE gel at 50 V for a total of 1,100 V-hours. A 59 32 P-labelled (with T4 PNK; NEB) l DNA-HindIII digest ladder (10,000 c.p.m.) was run as a marker on a separate lane on the gel. Next morning, the gel was shaken in 0.25 M HCl for 15 min followed by two rounds (15 min each) of shaking in solution containing 0.5 M NaOH and 1.5 M NaCl. Next, the gel was shaken in solution containing 0.5 M Tris-Cl and 1.5 M NaCl (pH 7.5) for 30 min. The gel was blotted on the positively charged Hybond N1 (GE) membrane in 103 SSC buffer (1.5 M NaCl, 0.15 M sodium citrate at pH 7.2) overnight by capillary blotting. Next morning, the membrane was irradiated with UV (260 nm; set at 1,200 mJ 3 100 energy) and prehybridized in 15 ml Rapid-hyb (GE) for 30 min at 50 uC in a hybridization oven with rotation. 59 32 P-labelled (with T4 PNK; NEB) telomeric probe of sequence (TTAGGG) 4 was added (20,000,000 c.p.m.) and hybridization was continued for 1 h at 50 uC. The hybridization solution was discarded and the membrane was rinsed three times with buffer containing 0.13 SSC and 0.1% SDS. The membrane was washed three times in this buffer at 50 uC, wrapped in Saran-wrap, exposed to a phosphorimager screen for 24-72 h, and analysed using the Imagequant TL software. The gel was calibrated using the known molecular weights of the l DNA-HindIII ladder and the mean telomere length for each lane was plotted as a function of population doubling for each cell line. A linear regression (MS Excel) was used to calculate the rate of telomere elongation. Quantitative RT-PCR. Total RNA was purified from the indicated cell lines using TRIzol reagent (Life Technologies). Total cDNA was prepared from total RNA using the High Capacity cDNA reverse transcription kit (Applied Biosystems). A fragment of the cDNA from endogenous TPP1 mRNA spanning a part of the 59 UTR (absent in Flag-tagged constructs) and continuing into the ORF was amplified, and qPCR was performed with the iQ SYBR green Supermix (Biorad) using the LightCycler 480 (Roche) equipment. Immunofluorescence (IF) and fluorescence in situ hybridization (FISH). For IF and FISH experiments, protocols were adapted from those described previously in the literature 27 and online sources (http://delangelab.rockefeller.edu/protocols. html). For TIF analysis using co-immunofluorescence (co-IF), 10,000 cells of HeLa-EM2-11ht-derived stable cell lines were seeded on coverslips in a 12-well culture plate containing growth medium adjusted to 200 ng ml 21 doxycycline. After 96 h, medium was removed and all subsequent steps were performed at room temperature. Cells were washed once with PBS and fixed with 3% or 4% formaldehyde in PBS for 8 min. The fixative was removed and the cells washed three times with PBS. The cells were permeabilized with PBS containing 0.1% Triton X-100 (PBS-T) for 5 min and blocked in PBS-T containing nuclease-free 3% BSA for 30 min. Cells were incubated with mouse monoclonal anti-TRF2 (Imgenex; IMG-124A; 1:500) and rabbit polyclonal anti-53BP1 (Novus Biologicals; NB100-304; 1:1,000 dilution) in PBS-T containing nuclease-free 3% BSA for 1 h. The cells were then washed three times in PBS (5 min each), and incubated with Alexa Fluor 568-conjugated anti-mouse IgG (Life Technologies) and Alexa Fluor 647-conjugated anti-rabbit IgG (Life Technologies) diluted 1:500 in PBS-T containing nuclease-free 3% BSA for 30 min in the dark. The cells were then washed three times in PBS and the excess PBS was removed by blotting. The coverslips were mounted on microscope slides using Vectashield mounting medium with DAPI (Vector Laboratories), sealed using transparent nail polish and stored at 4 uC or 220 uC until the time of imaging. Detection of Flag-TPP1 and RAP1 by co-IF was done essentially as above, but with mouse monoclonal anti-Flag M2 (Sigma; F1804; 1:500) and rabbit polyclonal anti-RAP1 (Novus Biologicals; NB100-292; 1:500) primary antibodies.
For combined immunofluorescence-fluorescence in situ hybridization (IF-FISH) experiments, the IF was performed before FISH. Briefly, IF was performed as described above using the appropriate primary and secondary antibodies. After the final PBS wash, the cells were fixed again in 4% formaldehyde in PBS for 10 min at room temperature. The cells were washed twice with PBS and dehydrated by successive 5-min incubations in 70%, 95% and 100% ethanol. The ethanol was removed and the coverslips allowed to dry for 2 min. The cells were rehydrated in 50% formamide in 23 SSC for 5 min. The coverslips were placed (with cells facing down) on a drop (,40 ml) of pre-hybridization solution containing 100 mg ml 21 dextran sulphate, 0.125 mg ml 21 E. coli tRNA, 1 mg ml 21 nuclease-free BSA, 0.5 mg ml 21 salmon sperm DNA, 1 mM vanadyl ribonucleoside complexes, and 50% formamide in 23 SSC for 1 h at 37 uC in a humidified chamber. Hybridization solution was made by adding a mixture of three Cy5-conjugated TR probes 27 (30 ng of each probe per coverslip) to the pre-hybridization solution and the cells were hybridized in this solution overnight at 37 uC in a dark humidified chamber. Next morning, the cells were washed twice in 50% formamide in 23 SSC and twice in PBS, and the coverslips were then mounted on microscope slides using ProLong Gold Antifade Reagent (Life Technologies). After 24 h at room temperature in the dark, the coverslips were sealed using transparent nail polish and stored at 4 uC or 220 uC until the time of imaging. In addition to antibodies mentioned above, rabbit polyclonal anti-coilin (Santa Cruz; sc-32860; 1:100) and Alexa Fluor 405conjugated anti-mouse (and anti-rabbit) IgG antibodies (Life Technologies; 1:500) were used to stain and image Flag-TPP1 and Cajal bodies. Microscopy. Imaging was performed using a Nikon TE2000-U inverted fluorescence microscope equipped with Photometrics Cascade II EM-CCD camera and Yokagowa Spinning disc Confocal (CSU-Xm2) (Nikon Instruments, Inc.) and a 603 oil objective. Images were acquired using Metamorph software. Linear image adjustments were made when necessary using ImageJ and Adobe Photoshop and applied to all images in a given channel. The colours depicted in the figures do not necessarily correspond to the emission of the fluorescent labels, but are used to facilitate visualization/analysis of 'merged' signals from two or more channels. Representative cells are shown in all microscopy figure panels. Quantification of co-localizations was done manually and plots of numbers of co-localizations per cell (one focal plane) show data obtained from 15 or more fields of cells (40-120 cells in total) for each sample set processed in parallel on the same day.
